Published in Clin Exp Immunol on January 01, 1994
Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest (2002) 1.82
New treatments addressing the pathophysiology of hereditary angioedema. Clin Mol Allergy (2008) 1.04
HAE therapies: past present and future. Allergy Asthma Clin Immunol (2010) 0.98
C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol (2005) 0.96
Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J (2011) 0.93
Rituximab therapy in a patient with low grade B-cell lymphoproliferative disease and concomitant acquired angioedema. J Asthma Allergy (2014) 0.81
Pathophysiology of Hereditary Angioedema. Pediatr Allergy Immunol Pulmonol (2014) 0.78
Life-threatening laryngeal oedema in a pregnant woman with hereditary angioedema. Ulster Med J (2000) 0.77
The pathophysiology of hereditary angioedema. World Allergy Organ J (2010) 0.75
Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med (1983) 2.18
COMPLEMENT AS A MEDIATOR OF INFLAMMATION. ENHANCEMENT OF VASCULAR PERMEABILITY BY PURIFIED HUMAN C'1 ESTERASE. J Exp Med (1963) 1.96
Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest (1975) 1.88
A radioimmunoassay for bradykinin in plasma and synovial fluid. J Lab Clin Med (1969) 1.79
A permeability factor released from guinea-pig serum by antigen-antibody precipitates. Br J Exp Pathol (1960) 1.48
Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med (1976) 1.45
Human C1 inhibitor: improved isolation and preliminary structural characterization. Biochemistry (1983) 1.37
Effect of C'1 esterase on vascular permeability in man: studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J Clin Invest (1968) 1.32
Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. J Clin Invest (1969) 1.27
Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol (1983) 1.25
Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Physicians (1977) 1.16
Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med (1980) 1.16
Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood (1991) 1.01
Purification of subcomponents Clq, Cl(-)r and Cl(-)s of the first component of complement from Cohn Fraction I by affinity chromatography. Prep Biochem (1980) 0.98
Angioedema induced by a peptide derived from complement component C2. J Exp Med (1988) 0.97
Homozygous C3 deficiency: detection of C3 by radioimmunoassay. Clin Immunol Immunopathol (1977) 0.94
C1s-induced vascular permeability in C2-deficient guinea pigs. J Immunol (1986) 0.91
Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma. J Clin Invest (1977) 0.89
Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE). Clin Exp Immunol (1982) 0.87
Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency. Immunology (1985) 0.86
Kinin generation in hereditary angioneurotic edema (H.A.N.E.) plasma. Adv Exp Med Biol (1983) 0.84
Inhibition of C1s-induced vascular leakage in guinea pigs by substituted benzamidine and pyridinium compounds. J Immunol (1977) 0.79
Recurrent Retinal Hemorrhages Occurring in the Young, with the Report of a Case. Trans Am Ophthalmol Soc (1912) 3.44
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry (1986) 2.52
Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody. J Clin Microbiol (1979) 1.97
Structural and functional division into two domains of the large (100- to 115-kDa) chains of the clathrin-associated protein complex AP-2. Proc Natl Acad Sci U S A (1989) 1.91
Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest (1971) 1.83
Hereditary angioneurotic edema: a clinical survey. Pediatrics (1966) 1.75
Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome. Proc Natl Acad Sci U S A (1989) 1.73
Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. J Exp Med (1968) 1.57
Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med (1976) 1.45
The prevention of hospitalization in schizophrenia: five years after an experimental program. Am J Orthopsychiatry (1972) 1.45
Degradation of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins. J Biol Chem (1984) 1.44
Evaluation of the Honeywell ACS 1000. Am J Med Technol (1977) 1.40
Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma. Circ Res (1974) 1.38
Hageman factor: alterations in physical properties during activation. Science (1965) 1.34
Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci U S A (1977) 1.34
Purification and chemical composition of gpL115, the human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome. J Biol Chem (1986) 1.33
Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol (1984) 1.32
Effect of C'1 esterase on vascular permeability in man: studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J Clin Invest (1968) 1.32
Serum inhibitor of C'1-esterase in health and disease. J Lab Clin Med (1966) 1.31
Remissions induced in hereditary angioneurotic edema with an attenuated androgen (danazol): correlation between concentrations of C1-inhibitor and the forth and second components of complement. J Lab Clin Med (1978) 1.31
Double-blind trial of cholestyramine in post-vagotomy diarrhoea. Gut (1977) 1.28
Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. J Clin Invest (1969) 1.27
Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans. J Clin Invest (1977) 1.26
CpG mutations in the reactive site of human C1 inhibitor. J Biol Chem (1989) 1.26
Activation of complement by a monoclonal cryoglobulin associated with cold urticaria. J Lab Clin Med (1969) 1.20
The effect of diet on lactase activity in the rat. Gastroenterology (1971) 1.19
Complications of removing percutaneous endoscopic gastrostomy tubes in children. J Pediatr Gastroenterol Nutr (2000) 1.18
Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies. J Clin Invest (1985) 1.18
Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Physicians (1977) 1.16
Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med (1980) 1.12
Biosynthesis of complement by human monocytes. Clin Immunol Immunopathol (1981) 1.10
Liver disease and cell-mediated immunity in hepatitis-associated antigen (HAA) carriers. Gut (1973) 1.10
Structural characterization of factor I mediated cleavage of the third component of complement. Biochemistry (1982) 1.09
Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways. J Virol (1993) 1.09
Occupational stress, safety, and health: conceptual framework and principles for effective prevention interventions. J Occup Health Psychol (1996) 1.08
Paramyosin is the Schistosoma mansoni (Trematoda) homologue of antigen B from Taenia solium (Cestoda). Mol Biochem Parasitol (1991) 1.08
Serum and Lens-Antigen Extract Treatment for the Prevention and Cure of Cataract: With the Report of the Results Obtained in One Hundred and Thirty-one Cataracts. Trans Am Ophthalmol Soc (1924) 1.07
A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem (1993) 1.06
Complement-dependent histaminase release from human granulocytes. J Clin Invest (1979) 1.04
Human inhibitor of the first component of complement, C1: characterization of cDNA clones and localization of the gene to chromosome 11. Proc Natl Acad Sci U S A (1986) 1.03
Lactose intolerance in Singapore. Gastroenterology (1970) 1.02
The C5a receptor is expressed by human renal proximal tubular epithelial cells. Clin Exp Immunol (2000) 1.02
Bovine conglutinin is a collagen-like protein. Biochemistry (1984) 1.02
Ultrastructure and composition of bovine conglutinin. Biochem J (1986) 1.02
Effects of ethyl alcohol on sphincteric resistance at the choledocho-duodenal junction in man. Gut (1968) 0.98
Lactose intolerance in asians. Nature (1967) 0.98
Angioedema induced by a peptide derived from complement component C2. J Exp Med (1988) 0.97
Suppression of rejection of Nippostrongylus brasiliensis in iron and protein deficient rats: effect of syngeneic lymphocyte transfer. Gut (1978) 0.97
Blood coagulation and related plasma enzymes in inflammation. Ser Haematol (1970) 0.96
Regulation of C1 inhibitor synthesis. Immunobiology (1998) 0.95
Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest (1987) 0.95
An action research approach to workplace health: integrating methods. Health Educ Q (1992) 0.95
C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clin Exp Immunol (2002) 0.94
Homozygous C3 deficiency: detection of C3 by radioimmunoassay. Clin Immunol Immunopathol (1977) 0.94
Histopathology in giardiasis: a correlation with diarrhoea. Aust N Z J Med (1978) 0.94
Recombinations between Alu repeat sequences that result in partial deletions within the C1 inhibitor gene. Genomics (1990) 0.93
Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc Natl Acad Sci U S A (1990) 0.93
Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children. Clin Nephrol (1978) 0.93
Purification of Hageman factor (factor XII) on columns of popcorn-agarose. Blood (1986) 0.92
The histopathological changes in the thymus gland in the acquired immune deficiency syndrome. Ann N Y Acad Sci (1984) 0.92
Action research on occupational stress: involving workers as researchers. Int J Health Serv (1989) 0.91
Transfer of C3 nephritic factor from mother to fetus. Is C3 nephritic factor IgG? N Engl J Med (1977) 0.91
Association of alternative complement pathway components with human blood platelets: secretion and localization of factor D and beta 1H Globulin. Clin Immunol Immunopathol (1981) 0.91
Human factor D of the alternative complement pathway. Physicochemical characteristics and N-terminal amino acid sequence. Biochemistry (1979) 0.90
Gangrene of the tongue caused by temporal arteritis. Med J Aust (1966) 0.90
Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema. Ann Intern Med (1977) 0.90
Localization of the human complement component C3 binding site on the IgG heavy chain. J Biol Chem (1991) 0.90
Inhibition of the adsorption of Hagemen factor (Factor XII) to glass by normal human plasma. J Lab Clin Med (1974) 0.89
Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma. J Clin Invest (1977) 0.89
Defective esterase and kinin-forming activity in human Fletcher trait plasma. A fraction rich in kallikreinlike activity. Circ Res (1974) 0.89
The C3b inactivator of the human complement system: homology with serine proteases. FEBS Lett (1981) 0.89
Adaptation of intestinal lactase in the rat. Gastroenterology (1969) 0.88
Lactose intolerance in various ethnic groups in South-East Asia. Australas Ann Med (1968) 0.88
Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor. J Pediatr (2001) 0.88
Frequency and etiology of gross hematuria in a general pediatric setting. Pediatrics (1977) 0.88
Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene. Proc Natl Acad Sci U S A (1990) 0.87
Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon. J Clin Invest (1989) 0.87
Surveillance nurse helps infection control. Mod Hosp (1966) 0.87
Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein. J Clin Invest (1995) 0.87
Hemispheric asymmetry: frequency analysis of visual and auditory evoked responses to non-verbal stimuli. Electroencephalogr Clin Neurophysiol (1974) 0.87
Transcriptional regulation of the C1 inhibitor gene by gamma-interferon. J Biol Chem (1994) 0.86
Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema. J Clin Invest (1987) 0.86
Contiguous deletion and duplication mutations resulting in type 1 hereditary angioneurotic edema. Hum Genet (1994) 0.86
The effects of ethyl alcohol on pancreatic exocrine function. Med J Aust (1966) 0.85
Preventing feeding-associated aspiration. Medsurg Nurs (1995) 0.85
Cooperative interaction of factor B and other complement components with mononuclear cells in the antibody-independent lysis of xenogeneic erythrocytes. J Exp Med (1982) 0.84
Kinin generation in hereditary angioneurotic edema (H.A.N.E.) plasma. Adv Exp Med Biol (1983) 0.84
Functional analysis of the serpin domain of C1 inhibitor. J Immunol (1994) 0.84
Cultured human glomerular mesangial cells express the C5a receptor. Kidney Int (1998) 0.84
Effect of pressure on the integrity of the duct-acinar system of the pancreas. Gut (1970) 0.84
Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera. J Immunol (1977) 0.84
Immunization against influenza in children with cancer: results of a three-dose trial. J Infect Dis (1982) 0.84
Effect of some analogues of bradykinin upon vascular permeability. Proc Soc Exp Biol Med (1967) 0.83
A cluster of mutations within a short triplet repeat in the C1 inhibitor gene. Proc Natl Acad Sci U S A (1994) 0.83